Liposomes hold great potential as gene and drug delivery vehicles due to their
biocompatibility and modular properties, coupled with the major advantage of attenuating …

The characteristics of the primary tumor blood vessels and the tumor microenvironment drive
the enhanced permeability and retention (EPR) effect, which confers an advantage towards …

Remarkable progress has recently been made in the synthesis and characterization of
engineered nanoparticles for imaging and treatment of cancers, resulting in several …

While liposome-mediated delivery of cytotoxic chemotherapy has been shown to
significantly enhance drug tolerability in patients as compared to the conventional …

The exploitation of nanosized materials for the delivery of therapeutic agents is already a
clinical reality and still holds unrealized potential for the treatment of a variety of diseases …

We herein review various pharmacological and clinical aspects of pegylated liposomal
doxorubicin (PLD), the first nanomedicine to be approved for cancer therapy, and discuss …

Tumor-associated macrophages (TAMs) generally display an immunosuppressive M2
phenotype and promote tumor progression and metastasis, suggesting their potential value …

Despite considerable advances in the application of liposomal drug delivery systems in
cancer treatment, the clinical application of liposomal formulations has been limited by many …

Nanoparticle-based anticancer medications were first approved for cancer treatment almost
2 decades ago. Patients benefit from these approaches because of the targeted-drug …

Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have
created revolutionary drug delivery systems in cancer over the past decade. While these …